Idiopathic Thrombocytopenic Purpura in Pregnancy

D Sithara, KS Rajeswari, M Sivasundari

ABSTRACT

Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder caused by development of IgG autoantibodies, directed against a number of platelet glycoproteins. A 26 years, primigravida, booked from 30 weeks of gestation, admitted at Sri Ramachandra Medical College and Hospital at 36 weeks of gestation, with gestational hypertension and severe thrombocytopenia with a platelet count of 45,000/mm$^3$. She was treated with intravenous steroids during her antenatal period for thrombocytopenia. She delivered a healthy baby girl of weight 2.4 kg by cesarean section and was breastfed. Intraoperatively, platelet transfusion was given. Postoperatively, she was on methyl prednisolone following which a good increment in the platelet count was noticed and then discharged. The aim is to clarify when thrombocytopenia in pregnancy is clinically important, to provide guidance regarding diagnosis, management options and information about potential risks to the mother and the fetus along with the review of relevant literatures.

Keywords: Corticosteroid, Idiopathic thrombocytopenia, Pregnancy.

INTRODUCTION

Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder, with a platelet count often $<80 \times 10^9/l$, induced by platelet-specific IgG antibodies. The great concern of ITP during pregnancy is the risk of thrombocytopenia in the newborn infant. ITP accounts for 3 to 4% of the cases of thrombocytopenia detected in pregnancy. It has many common causes which includes gestational thrombocytopenia, bacterial and viral infections, pre-eclampsia complicated by HELLP syndrome. We present here a case of ITP in pregnancy for its rarity and unique presentation who posed a therapeutic challenge.

CASE REPORT

A 26-year-old primigravida who presented in her 30th week of gestation with severe epistaxis. Her platelet count was ranging between 10,000 and 30,000/mm$^3$ for which she was treated with intravenous steroids. Steroids were also covered for prematurity. She was on methyl prednisolone following which a good increment in the platelet count was noticed and then discharged. The aim is to clarify when thrombocytopenia in pregnancy is clinically important, to provide guidance regarding diagnosis, management options and information about potential risks to the mother and the fetus along with the review of relevant literatures.

Keywords: Corticosteroid, Idiopathic thrombocytopenia, Pregnancy.
counts improved to 1.8 l/mm³ on the ninth postoperative day and she was discharged home.

DISCUSSION

Idiopathic thrombocytopenic purpura affects 1 to 3 per 1000 pregnancies. During pregnancy, hemodilution caused by relative increase in plasma volume coupled with increased platelet turnover leads to the development of thrombocytopenia, accounting for three quarters of cases detected during pregnancy. Idiopathic thrombocytopenic purpura is of three degrees. Mild thrombocytopenia, platelet count <1.5 l/mm³. Moderate thrombocytopenia, platelet count <1 l/mm³. Severe thrombocytopenia, platelet count <0.5 l/mm³. Presenting symptoms include bruising, epistaxis, gum bleeding, petechial rash, more significant hemorrhage, however, increasingly asymptomatic women are diagnosed. Diagnostic approach is the same as in the non-pregnant state. Exclusion of all other causes of thrombocytopenia and other possible autoimmune disorders, and exclusion of HIV is mandatory. Effects on pregnancy include affection on the fetus and of the mother. Intracranial hemorrhage, the most feared complication of neonatal thrombocytopenia. Maternal issues include spontaneous bleeding posing a low incidence. If planning for delivery, platelet requirements include >50,000/mm³ for vaginal delivery, >80,000/mm³ for emergency cesarean section and usually 80,000 to 1,00,000/mm³ for elective cesarean section. What constitutes a safe platelet level for pregnancy and delivery has not been determined. Treatment options are just the same as in the nonpregnant women. First line is with corticosteroids, especially prednisone, which is metabolized by the placenta, so has minimal fetal side effects but increases the risk of coexisting conditions, like gestational diabetes, hypertension infections, preterm labor for the mother. Splenectomy can be considered if not responding to medical therapy. Laproscopic approach can be safely carried out in the second trimester. Intravenous immunoglobulin, swamps the IgG Fc receptors of macrophages in spleen, providing platelet count improvements. Rituximab, a monoclonal antibody therapy, is not clear though, as it crosses the placenta causing temporary suppression of B lymphocytes and long-term effect on infant’s immune system development. Thrombocytopenia may limit the choices of anesthesia, but the mode of delivery is determined by obstetric indications. Finally, all neonates born to ITP mothers should be screened. Treatment options include intravenous immunoglobulins and platelet transfusion. In case of severe manifestations, rare possibility of coexistent neonatal autoimmune thrombocytopenia (NAIT) has to be excluded. Thus, it poses a diagnostic and a therapeutic challenge.

REFERENCES